Sunitinib

Form: Tablet

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg

Reference Brands: Sutent® (EU & US)

Category: Oncology Cancer Care

Sunitinib Tablets are oral tyrosine kinase inhibitors used to treat renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. Available in 12.5 mg, 25 mg, 37.5 mg, and 50 mg film-coated tablets, our products comply with EU-GMP and USFDA standards. Offered for B2B supply, contract manufacturing, and private labeling, Sunitinib comes with full regulatory documentation including CTD dossiers and bioequivalence data. Trusted by distributors and hospital pharmacies across the US and EU, these tablets ensure consistent quality and efficacy for oncology treatment programs in regulated markets.